Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The power of simplicity.

J Lange1

  • 1National AIDS Therapy Evaluation Centre, Academic Medical Centre, Amsterdam, The Netherlands. j.lange@amc.uva.nl

International Journal of STD & AIDS
|November 18, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GW170817: Observation of Gravitational Waves from a Binary Neutron Star Inspiral.

Physical review letters·2017
Same author

GW170814: A Three-Detector Observation of Gravitational Waves from a Binary Black Hole Coalescence.

Physical review letters·2017
Same author

EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy.

Allergy·2017
Same author

GW170104: Observation of a 50-Solar-Mass Binary Black Hole Coalescence at Redshift 0.2.

Physical review letters·2017
Same author

Upper Limits on the Stochastic Gravitational-Wave Background from Advanced LIGO's First Observing Run.

Physical review letters·2017
Same author

Directional Limits on Persistent Gravitational Waves from Advanced LIGO's First Observing Run.

Physical review letters·2017

Didanosine is a potent nucleoside analogue effective in various therapies, with low resistance rates. Its once-daily enteric-coated formulation improves adherence and virological control.

Area of Science:

  • Pharmacology
  • Virology
  • Infectious Diseases

Background:

  • Didanosine is a potent nucleoside analogue with a long history of use.
  • Its efficacy has been proven in monotherapy, dual therapy, and triple therapy regimens.
  • Older formulations were associated with gastrointestinal side effects, impacting patient adherence.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of didanosine.
  • To assess the resistance profile of didanosine compared to other nucleoside analogues.
  • To highlight the benefits of the once-daily, enteric-coated formulation.

Main Methods:

  • Clinical use and efficacy data analysis.
  • Phenotypic resistance prevalence assessment.
  • Comparison with other nucleoside analogue therapies.

Related Experiment Videos

Main Results:

  • Didanosine demonstrates high potency across different therapeutic combinations.
  • The enteric-coated formulation reduces gastrointestinal side effects, enhancing adherence and virological control.
  • Low prevalence of phenotypic nucleoside resistance to didanosine, requiring at least 6 mutations for resistance.
  • Didanosine remains effective in patients with M184V mutation who have failed lamivudine therapy.

Conclusions:

  • Enteric-coated didanosine is a potent and well-tolerated option for HIV treatment.
  • Its low resistance profile and ease of administration make it valuable in early therapy and salvage regimens.
  • Improved adherence due to once-daily dosing contributes to better virological outcomes.